Gastroesophageal reflux (GER) is defined as the passage of gastric contents into the esophagus. It occurs in healthy infants and can be considered physiological process. Uncomplicated GER can present with recurrent vomiting or regurgitation without any other symptoms and is usually managed by educating, reassuring, and guiding the parent without other intervention. GER disease (GERD) refers to the appearance of troublesome symptoms or complications (erosive esophagitis, ulceration, Barrett's esophagus) and may warrant acid suppression. Proton Pump Inhibitors (PPIs) are the most effective pharmacologic agents available for the treatment of children with GERD. In the pediatric practice only omeprazole, lansoprazole and esomeprazole are available over the first year of life. The empiric use in infants with nonspecific symptoms (excessive crying, regurgitation, feeding refusal, chronic cough) is frequent without randomized controlled study. Our paper will focus on the correct indications, dosages, duration of treatment and safety of PPI use in pediatric population.
Keywords: Proton Pump Inhibitors, GERD, children, OMEPRAZOLE, LANSOPRAZOLE, ESOMEPRAZOLE, drug, –, drug interactions, drug-induced hypochlorhydria, Rabeprazole, Lower Esophageal Sphincter, Apparent Life- Threatening Events, Histamine 2- receptor antagonist, Gastroesophageal Reflux
Rights & PermissionsPrintExport